Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375].
ESMO Open
; 8(2): 101185, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-36868156
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
ESMO Open
Year:
2023
Document type:
Article
Country of publication: